NKNikolay Kislov

Nikolay Kislov

*This is an algorithmically generated author record based on publicly available information.

Nikolay Kislov has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial

    by Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina Orlova, Vladimir Moiseenko, Igor Utyashev, Daniil Stroyakovskiy, Vadim Kozlov, Anastasia Zimina, Anastasia Mochalova, et al.


  • Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

    by L. G. Zhukova, E. V. Artamonova, S. A. Demidova, К. Д. Пеньков, П. В. Криворотько, O. A. Gladkov, N. V. Kovalenko, N. A. Falaleeva, R. I. Kunafina, L. Yu. Vladimirova, et al.

    Introduction. The increasing need for affordable treatment options for patients with HER2-positive breast cancer necessitates the development of pertuzumab biosimilars to expand access to effective therapies. BCD-178 is a pertuzumab biosimilar that has demonstrated equivalence to reference pertuzumab (RP) based on physicochemical characterization, preclinical in vitro and in vivo and clinical phase I study. The international, multicenter, Phase III clinical trial BCD-178–2/PREFER was conducted to comparatively evaluate the efficacy and safety of BCD-178 and RP in combination with TCHP regimen for neoadjuvant therapy in patients with HER2-positive breast cancer.Objective. To compare the efficacy and safety of the pertuzumab biosimilar BCD-178 and RP when used in a neoadjuvant setting for patients with HER2-positive breast cancer.Methods. The study included female patients aged 18–75 years with histologically confirmed invasive HER2-positive breast cancer and the absence of estrogen receptor (ER) and progesterone receptor (PR) expression. Patients were randomized 1:1 to receive either BCD-178 or RP. The primary endpoint was the proportion of patients achieving a total pathological complete response – tpCR (ypT0/is, ypN 0) based on the conclusion of a central independent review after completion of the neoadjuvant therapy phase.Results. A total of 380 patients were randomized into the study. The proportions of patients achieving tpCR (95 % CI) were not statistically different between the treatment groups (p=0.6521, Cochran–Mantel–Haenszel method). The risk difference (95 % CI) for achieving tpCR between the groups was within the pre-defined equivalence boundaries, demonstrating equivalent efficacy of BCD-178 and RP. The treatment groups were comparable in terms of safety profile, including the incidence of adverse reactions (ARs). The most common (≥10 % of patients) ARs were diarrhea and anemia. The pharmacokinetics and immunogenicity of the drugs were comparable.Conclusions. The study demonstrated comparability between BCD-178 and RP in terms of efficacy, safety, pharmacokinetics, and immunogenicity when used in the neoadjuvant treatment of patients with HER2-positive ER/PR-negative breast cancer.

  • Open Access

    Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study

    by Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, et al.

    Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstrated the efficacy and safety of ribociclib in combination with aromatase inhibitors as a first-line treatment in post- and premenopausal patients. In the Phase lllb CompLEEment-1 study, the same treatment regimen was evaluated in an extended patient population in terms of both safety and efficacy. The article presents an analysis of data from a subgroup of patients from Russia. Materials and methods. The study included 129 patients from Russia who met the inclusion criteria for the CompLEEment-1 study. The primary endpoint was the incidence of adverse events (AEs) at a median follow-up of 25.4 months. Secondary endpoints were median progression-free survival, objective response rate, and disease control. Results. The efficacy and safety results of the therapy in the subgroup of patients from Russia were consistent with the general population of patients included in CompLEEment-1. The incidence of AEs requiring dose adjustment or treatment interruption was 58.1%, and the permanent discontinuation rate was 15.5%. The most frequently reported treatment-related AEs grade 3 or higher were neutropenia and transaminase increased. Conclusion Data obtained in a subgroup of patients from the Russian Federation confirm the safety and tolerability of ribociclib in an extended population of patients with HR+/HER2- breast cancer in settings close to the real world.

  • Open Access

    Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

    by Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, et al.

    Purpose:To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib.Experimental Design:Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included. Retrospective analyses of the association between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab plus axitinib or sunitinib arms were performed using the first interim analysis of the phase 3 JAVELIN Renal 101 trial (NCT02684006). Multivariate Cox regression analyses of PFS and OS were conducted. Translational data were assessed to elucidate the underlying biology associated with differences in NLR.Results:Patients with below-median NLR had longer observed PFS with avelumab plus axitinib [stratified HR, 0.85; 95% confidence interval (CI), 0.634–1.153] or sunitinib (HR, 0.56; 95% CI, 0.415–0.745). In the avelumab plus axitinib or sunitinib arms, respectively, median PFS was 13.8 and 11.2 months in patients with below-median NLR, and 13.3 and 5.6 months in patients with median-or-higher NLR. Below-median NLR was also associated with longer observed OS in the avelumab plus axitinib (HR, 0.51; 95% CI, 0.300–0.871) and sunitinib arms (HR, 0.30; 95% CI, 0.174–0.511). Tumor analyses showed an association between NLR and key biological characteristics, suggesting a role of NLR in underlying mechanisms influencing clinical outcome.Conclusions:Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.

  • Open Access

    Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

    by Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, et al.

    Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

  • Open Access

    Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

    by Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, et al.

    Purpose:To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib.Experimental Design:Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included. Retrospective analyses of the association between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab plus axitinib or sunitinib arms were performed using the first interim analysis of the phase 3 JAVELIN Renal 101 trial (NCT02684006). Multivariate Cox regression analyses of PFS and OS were conducted. Translational data were assessed to elucidate the underlying biology associated with differences in NLR.Results:Patients with below-median NLR had longer observed PFS with avelumab plus axitinib [stratified HR, 0.85; 95% confidence interval (CI), 0.634–1.153] or sunitinib (HR, 0.56; 95% CI, 0.415–0.745). In the avelumab plus axitinib or sunitinib arms, respectively, median PFS was 13.8 and 11.2 months in patients with below-median NLR, and 13.3 and 5.6 months in patients with median-or-higher NLR. Below-median NLR was also associated with longer observed OS in the avelumab plus axitinib (HR, 0.51; 95% CI, 0.300–0.871) and sunitinib arms (HR, 0.30; 95% CI, 0.174–0.511). Tumor analyses showed an association between NLR and key biological characteristics, suggesting a role of NLR in underlying mechanisms influencing clinical outcome.Conclusions:Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.

  • Open Access

    Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

    by Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, et al.

    Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

  • The impact of therapeutic enteral nutrition on quality of life in cancer patients in need of palliative care

    by G.M. Manikhas, V.M. Luft, R.O. Dreval, V.G. Elishev, A.N. Zhigulev, N.V. Kislov

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность применения энтерального питания в амбулаторно-поликлинических условиях при лечении паллиативных онкологических больных со злокачественными новообразованиями (ЗНО) желудка, губы, полости рта и глотки. МАТЕРИАЛ И МЕТОДЫ Проведено ретроспективное сравнительное исследование, в которое вошло 288 паллиативных онкологических пациентов, получавших специализированную медицинскую помощь. В 1-й группе (n=155) больные дополнительно к основному рациону получали специализированные энтеральные питательные смеси (ЭПС), во 2-й группе (n=133) — только лечебный рацион питания. Проанализированы данные по локализации ЗНО, возрастной и половой структуре пациентов, длительности, объему и переносимости энтерального питания. Проводили сравнительную оценку динамики массы тела и индекса массы тела (ИМТ). Изучали субъективную оценку органолептических качеств потребляемых ЭПС, вкусовые предпочтения и приверженность больных к энтеральному питанию в зависимости от локализации ЗНО. Дана оценка динамики качества жизни пациентов по шкале ECOG. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Анализ данных наблюдения паллиативных больных со ЗНО губы, полости рта, глотки и желудка показал, что до 39% на момент установления диагноза имели ИМТ менее 20 кг/м2 (12% менее 17 кг/м2). Выявлена прямая корреляционная зависимость динамики показателей ИМТ с применением ЭПС. В 1-й группе пациентов, применявших ЭПС, показатели ИМТ имели менее выраженную динамику падения, чем средние значения ИМТ у больных контрольной группы, у которых, начиная с 3-го месяца наблюдения, отмечалась более значимая редукция массы и ИМТ, превышавшая таковую в 1-й группе на 6,4%. ЗАКЛЮЧЕНИЕ Нутритивная поддержка паллиативных пациентов с применением в качестве дополнительного источника питания специализированных ЭПС не менее 3 мес достоверно снижает выраженность потери массы тела, что напрямую сопряжено с улучшением их качества жизни по сравнению с контрольной группой больных. Дополнительное применение специализированных ЭПС (сипинга) улучшает качество жизни больных со ЗНО: 46% пациентов отметили улучшение самочувствия и почти в 2 раза выросла положительная субъективная оценка их качества жизни (с 28 до 52%). При назначении ЭПС следует учитывать сенсорные вкусовые предпочтения паллиативных пациентов. Наиболее востребованными были ЭПС со вкусом «Капучино» (44%) и нейтральным вкусом (19%).


  • Open Access

    Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

    by Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, et al.

    Purpose: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. Experimental Design: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included. Retrospective analyses of the association between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab plus axitinib or sunitinib arms were performed using the first interim analysis of the phase 3 JAVELIN Renal 101 trial (NCT02684006). Multivariate Cox regression analyses of PFS and OS were conducted. Translational data were assessed to elucidate the underlying biology associated with differences in NLR. Results: Patients with below-median NLR had longer observed PFS with avelumab plus axitinib [stratified HR, 0.85; 95% confidence interval (CI), 0.634–1.153] or sunitinib (HR, 0.56; 95% CI, 0.415–0.745). In the avelumab plus axitinib or sunitinib arms, respectively, median PFS was 13.8 and 11.2 months in patients with below-median NLR, and 13.3 and 5.6 months in patients with median-or-higher NLR. Below-median NLR was also associated with longer observed OS in the avelumab plus axitinib (HR, 0.51; 95% CI, 0.300–0.871) and sunitinib arms (HR, 0.30; 95% CI, 0.174–0.511). Tumor analyses showed an association between NLR and key biological characteristics, suggesting a role of NLR in underlying mechanisms influencing clinical outcome. Conclusions: Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.


  • Open Access

    Regional clinical and economic model of colorectal cancer screening

    by P. V. Nesterov, A. V. Ukharskiy, N. V. Kislov

    Purpose of the study. To evaluate the clinical and economic efficiency of colorectal cancer screening model in the Yaroslavl region. Materials and methods. To achieve this goal, we have given a clinical and economic assessment of the existing approach to the diagnosis and treatment of colon cancer. We have also developed a clinical and economic model of colorectal cancer screening strategy in the Yaroslavl region. After that, we made a comparative assessment between the strategies on such parameters as total costs, efficiency, and CER coefficient. Results. The strategy for the absence of colorectal cancer screening has a cost-effectiveness rate equal to 246 712 rubles (3820$)/LYG, with the value of added years of life in 2.9 years. According to our calculations, the implementation of the program of screening of CRC based on fecal occult blood immunochemical method, followed by the implementation of colonoscopy in the case of a positive result, will require an increase in funding for patients with colon cancer by 6.9% per year. At the same time, by changing the structure of morbidity and increasing the part of early forms in the implementation of the screening program, an increase in the estimated life expectancy of patients will be achieved, which is consistent with the long-term results of programs conducted in Europe and the United States. The CER for the screening strategy is 103.95 thousand rubles (2030$) / LYG. Long-term modeling shows that the introduction of screening program will reduce the incidence of CRC by 12% from the baseline by the 15th year of implementation and reduce the cost of diagnosis and treatment of colon cancer by 16.1% per year without taking into account inflation expectations. Conclusion. The introduction of a colorectal cancer-screening program at the regional level is clinically effective and cost-effective.